Aprea bets seven new trial sites on two partial responses in 28 patients
The evidence behind the expansion is two partial responses and six stable diseases among 28 heavily pretreated patients, with both detailed responders carrying a PPP2R1A mutation. The point of adding sites is to find out whether that pattern holds.
The Scientist · Science desk
What happened
- Aprea is taking its ACESOT-1051 dose-escalation trial of the WEE1 inhibitor APR-1051 from three active clinical sites to 10, more than tripling the network enrolling patients.
- The ASCO 2026 poster reported preliminary activity in eight of 28 patients, made up of two partial responses and six patients whose disease stabilized, as of a May 6 data cutoff.
- The response Aprea presented at ASCO was in a patient with PPP2R1A-mutated uterine serous carcinoma dosed at 150 mg, with target lesion size halved and CA-125 falling from 732 to 70 U/mL.
- The company now plans to enroll at least 50 patients with uterine serous carcinoma or Cyclin E-overexpressing platinum-resistant ovarian cancer, and to add combination arms alongside standard of care.
- Dose escalation and backfill expansion are expected to finish in the second quarter of 2027, with an updated data presentation at a medical meeting due in the fourth quarter.
Why it matters
- decision The population that will be tested for survival benefit is being chosen now, off single-digit response counts, which is why Gilad describes dose escalation as the place to spend money rather than the place to save it.
- constraint Even a much larger fourth-quarter dataset stays single-arm and uncontrolled, so the strongest available inference is response rate inside a mutation-defined group, not evidence of benefit over standard care.
- exposure Reusing single-agent dose levels in the combination arms saves a round of dose finding, and it also puts the tolerability profile at risk in the one setting where hematologic toxicity is hardest to attribute.
- precedent If PPP2R1A status rather than tumor histology turns out to select responders, mutation-selected enrollment becomes the design other DNA-damage-response programs will be asked to justify departing from.
The denominator is doing all the work here. Two partial responses among 28 patients is a 7.1% response rate [22], and nobody opens seven new sites [23] on 7.1%. But Aprea has publicly detailed two responding patients, both with PPP2R1A-mutated uterine or endometrial cancer, one dosed at 150 mg and one at 220 mg [15][13], and uterine or endometrial patients were 8 of the 28 enrolled [18]. If both responses came from inside that group of eight, the rate within it is 25% [26] and the trial-wide figure is really describing a mixture of tumor types.
How many of the 28 carried a PPP2R1A mutation is not stated in the poster [17]. Without that count, 25% is a ceiling drawn around a subgroup whose true size is unknown, which is precisely the number the expansion is designed to produce. Aprea's stated aim is to characterize activity in biomarker-defined populations with a mechanistic rationale for WEE1 inhibition [6], and CEO Oren Gilad told GEN the goal is to identify who responds most strongly so that population can be carried into the next phase [11].
The accrual arithmetic is the reason Q4 is the date to hold them to. Six to 10 patients a month [3] means the study adds as many patients in roughly three to five months as it had enrolled in total by the May 6 cutoff [24]. The planned cohort of at least 50 patients with uterine serous carcinoma or Cyclin E-overexpressing platinum-resistant ovarian cancer [7] is about 1.8 times the entire reported dose-escalation population [25]. So the Q4 update should be the first version of this dataset where a mutation-selected group has a denominator worth quoting.
Two cautions on what that update can and cannot settle. It will still be single-arm. In patients with a median of three prior lines of treatment [21], a 50% lesion reduction is hard to attribute to anything but the drug, which is why the two partial responses carry more weight than the six stable diseases; stable disease in this setting has no comparator, and the source reports no durations [19]. And the CA-125 declines, 87% in one case and more than 90% in the other [13][15], are pharmacodynamic readouts. Gilad's own framing is that the next phase is about overall survival [12].
The combination arms are where the safety story gets its real test. Aprea plans to use dose levels that already showed single-agent activity and cleared safety review [9], layered onto standard of care in HPV-positive head and neck cancer and colorectal cancer [8]. The poster's authors concluded manageable safety with no substantial myelosuppression [20], which is easier to sustain as a single agent than on top of chemotherapy.
My read: this is a defensible use of dose-escalation money, conditional on one thing. Whether the tripling bought clarity or just speed depends on whether the Q4 presentation reports response and duration by mutation status, rather than another pooled advanced-solid-tumor rate.
What to watch
- Whether the fourth-quarter presentation reports responses by mutation status and gives the duration of each response and stabilization.
- Whether the combination arms can hold the single-agent dose levels once APR-1051 sits on top of standard of care.
- Whether monthly accrual actually reaches six to 10 patients with 10 sites open, since the second-quarter 2027 completion date depends on it.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence52
- Adoption17
- Hype gap+26
- Incentives74
- Confidence56
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Aprea Therapeutics is accelerating enrollment in the ongoing Phase I trial of APR-1051, one of its two lead programs, and expanding the indications under study after seeing early signs of clinical activity.
- [2]
The Phase I dose escalation trial ACESOT-1051 (NCT06260514) will accelerate enrollment, with Aprea planning to more than triple its active clinical sites from three to 10.
- [3]
The expansion is expected to raise monthly enrollment to between six and 10 patients by the fourth quarter.
- [4]
By the fourth quarter Aprea expects to share updated clinical data from the Phase I trial of APR-1051 at a medical meeting.
- [5]
APR-1051 is an oral small-molecule inhibitor of WEE1 kinase, a DNA damage response pathway protein; WEE1 regulates the G2 checkpoint, which ensures cells do not initiate mitosis until damaged DNA is repaired.
- [6]
The acceleration is intended to help Aprea further characterize the clinical activity of APR-1051 in biomarker-defined tumor populations with a mechanistic rationale for WEE1 inhibition.
- [7]
Aprea is advancing APR-1051 in uterine serous carcinoma and Cyclin E-overexpressing platinum-resistant ovarian cancer, and expects to enroll at least 50 patients with USC or PROC.
- [8]
Aprea is expanding the Phase I study to include combination arms enrolling HPV-positive head and neck squamous cell carcinoma and colorectal cancer, in combination with standard-of-care therapies.
- [9]
For both the new indication cohorts and the combination arms, Aprea said it will use APR-1051 dose levels that have shown single-agent activity and cleared safety review.
- [10]
Dose escalation and backfill expansion of the patient population is expected to be completed in the second quarter of 2027.
- [11]
Aprea president and CEO Oren Gilad told GEN: "Our goal is to see who is responding the strongest, who is the most sensitive to our therapy. These are the patient population that we're going to be then treating in the next phase of development."
- [12]
Gilad said that to de-risk the next phase of development, "which is all about overall survival," the company is spending substantial time and resources on the dose escalation stage.
- [13]
In March, Aprea said a patient with PPP2R1A-mutated endometrial cancer showed a confirmed partial response after treatment at a 220 mg dose, with a 50% reduction in target lesion size and an 87% decline in CA-125 from 362 to 47 U/mL.
- [14]
A later assessment of that patient showed an additional 9.5% reduction in target lesion size and CA-125 down to 40.2 U/mL.
- [15]
In January, Aprea disclosed that a patient with PPP2R1A-mutated uterine serous carcinoma showed a 50% reduction in target lesion size and a greater than 90% reduction in CA-125, from 732 to 70 U/mL, at the protocol-defined eight-week first imaging assessment after treatment at a 150 mg dose.
- [16]
Aprea presented early results from the first-in-human Phase 1 study of APR-1051 (ACESOT-1051) as a poster at the American Society of Clinical Oncology 2026 Annual Meeting.
- [17]
The ASCO presentation showed stable disease in six of 28 patients (23%) with advanced solid tumors harboring specific cancer-associated gene alterations, enrolled up to the 300 mg dose level as of the May 6 cutoff.
- [18]
Of the 28 enrolled patients, 14 had colorectal cancer, eight uterine or endometrial cancer, two pancreatic cancer, two HPV-related oropharyngeal squamous cell carcinoma, one breast cancer and one gastric cancer.
- [19]
Preliminary signs of clinical activity were seen in eight patients (29%), consisting of two partial responses and six patients with disease stabilization.
- [20]
Researchers concluded in the poster that APR-1051 "has shown manageable safety and early signs of tumor shrinkage and no substantial myelosuppression."
- [21]
Treatment-emergent adverse events of any grade were reported in 26 of the 28 patients, who had a median of three prior lines of treatment before being dosed with APR-1051.
- [22]
Two partial responses among 28 enrolled patients is an objective response rate of about 7.1%.
- [23]
Going from three active sites to 10 adds seven sites, a 3.3-fold increase.
- [24]
At six to 10 patients a month, the trial would add 28 patients in about 2.8 to 4.7 months, matching its entire enrollment as of the May 6 cutoff.
- [25]
The planned cohort of at least 50 USC or PROC patients is about 1.8 times the 28 patients reported in the dose-escalation data.
- [26]
If both partial responses occurred among the eight uterine or endometrial cancer patients, the response rate within that subgroup would be 25%.
Sources
1 independent publisher whose own reporting we read for this story.
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Topics
- Precision OncologyFollow
- Clinical Data CatalystsFollow
- DNA Damage Response InhibitorsFollow
- Early-Phase Clinical Trial OperationsFollow